A Study of Chios Mastic Water in Irritable Bowel Syndrome — MASTIQUA  

Irritable Bowel Syndrome Clinical Trial

Official title: The Effectiveness of a Natural Aqueous Extract of Chios Mastic in the Management of Irritable Bowel Syndrome: the MASTIQUA Randomized Controlled Clinical Trial

Status Completed

Clinical Trial Summary

Chios mastic is a natural product with strong antimicrobial, anti-inflammatory and antioxidant properties, and well-established benefits for dyspeptic disorders. The aim of the present study is to investigate the effectiveness of a natural aqueous extract of Chios mastic (mastic water), a by-product of Chios mastic processing, in the management of irritable bowel syndrome. This will be a 3-month randomized double-blind controlled clinical trial in adult patients with irritable bowel syndrome under standard medication. Participants will be blindly randomized to a low-dose mastic group, which will receive a carbonated water enriched with Chios mastic water (0.06%), a high-dose mastic group, which will receive a carbonated fruit juice enriched with Chios mastic water (0.55%), or one of the two control groups, which will receive an identical placebo water/fruit juice with no active ingredients. Participants will be evaluated in terms of anthropometric indices, lifestyle habits, severity of IBS-related gastrointestinal symptoms, quality of life, as well as biochemical, inflammatory and oxidative stress markers, both pre- and post-intervention.

Clinical Trial Description

Chios mastic is the resin of the mastic tree (Pistacia Lentiscus var. Chia), produced exclusively in the southern part of the Greek island of Chios. References about its medical use from local populations for the treatment of gastrointestinal disorders or as a cosmetic agent can be found in ancient texts. Nowadays, this versatile resin has been rediscovered, not only as a traditional remedy and aromatic agent, but as a potent phytotherapeutic product with strong anti-inflammatory, anti-microbial and anti-oxidant properties. In 2015, Chios mastic was recognized as a herbal medicinal product by the European Medicines Agency (EMA), with two therapeutic indications: mild dyspeptic disorders and skin inflammation/healing of minor wounds (EMA/HMPC/46758/2015). Over the last years, Chios mastic is widely used in medicinal products, food supplements and cosmetics and has become the object of intense study in the fields of Nutrition and Pharmacotechnology.

Irritable bowel syndrome (IBS) is a chronic functional gastrointestinal disease characterized by adverse changes in bowel function (frequency of bowel movements and/or stool composition) and abdominal pain. The clinical presentation of IBS usually includes symptoms of abdominal pain, flatulence, bloating, diarrhea and constipation that often alternate, while postprandial discomfort in the upper abdomen, feeling of fullness, nausea, vomiting and back pain are less commonly reported. IBS affects approximately 7-16% of the general population, and leads to reduced functionality and productivity and a significant deterioration in quality of life due to its various intestinal manifestations. The first-line pharmacological treatments for IBS aim at alleviating symptoms and include antispasmodics or anticonvulsants for abdominal pain, antidiarrheal medication and laxatives for constipation. Dietary modifications, such as the avoidance of foods that aggravate gastrointestinal symptoms and various types of exclusion diets, are also applied as adjunctive therapies for IBS management, but evidence of their effectiveness remains scares and inconclusive.

The use of foods/beverages enriched with Chios mastic could constitute a promising complementary approach for the management of IBS, in combination with current first-line pharmacological treatments. The aim of the present interventional study is to explore the effectiveness of a natural aqueous extract of Chios mastic in the management of IBS.

The study will be a 3-month parallel, randomized (allocation ratio 1:1), controlled, double-blind clinical trial in a sample of 60 adult patients with IBS. Eligible participants will be adult (18-65 years old) otherwise healthy individuals with an IBS diagnosis based on ROME IV criteria under stable medication. Participants will be excluded on the basis of the presence of other chronic gastrointestinal diseases, the presence of other serious comorbidities, or recent significant changes in lifestyle habits. Participants will be randomized to a low-dose mastic group (LDMG), a low-dose control group (LDCC), a high-dose mastic group (HDMG) or a high-dose control group (HDCC). The LDMG will be provided with 600 mL of a sparkling water (mastiqua) containing the natural mastic aqueous extract (0.06%) to be consumed daily (3 bottles of 200 mL each). The HDMG will be provided with 600 mL of a sparkling fruit juice (mastiqua lemon) containing the natural mastic aqueous extract (0.55%) to be consumed daily (3 bottles of 200 mL each). The LDCC and HDCC will receive the same quantity of a placebo sparkling water or fruit juice, respectively. For each type of drink (water and fruit juice), the intervention and placebo drinks will be unlabeled and identical in appearance and organoleptic characteristics, including the characteristic Chios mastic aroma. Randomization will be performed by an investigator with no clinical involvement, while all patients and study team members will be blinded to patient allocation in study groups.

All enrolled patients will continue their standard medical treatment which must remain stable throughout the trial. The study physician will systematically record potential side-effects and will be in charge of terminating the intervention if needed. Participants will be assessed in terms of anthropometric indices (body weight, height, waist circumference, and body composition), lifestyle habits (diet and physical activity habits), the presence and severity of gastrointestinal symptoms, and quality of life both pre- and post-intervention. In addition, blood samples after a 12-hour fast and morning urine samples will be collected to measure biochemical, inflammatory and oxidative stress markers. ;

Related Conditions & MeSH terms

• Irritable Bowel Syndrome
• Syndrome

• NCT number: NCT04893499
• Study type: Interventional
• Source: Rutgers, The State University of New Jersey
• Status: Completed
• Phase: N/A
• Start date: September 12, 2021
• Completion date: May 16, 2022